Eugene E. Marcantonio

Merck & Co., Inc., Rahway, NJ, USA (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial”.

Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102433

N/A

0.718DataRank · unranked

23 citations

Tokunbor A. Lawal, Irene C. Chrismer, Angela Kokkinis, Christopher Grunseich, Minal Jain +19 more